RECRUITING

Ultra-Low Contrast Angiography in AKI

Talk to us

Conditions

Acute Kidney InjuryCoronary angiographyUltra low contrast

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The aim of this study is to evaluate the safety of ultra-low contrast coronary angiography in patients with pre-existing acute kidney injury.

Official Title

Randomized Controlled Trial of Ultra-Low Contrast Coronary Angiography During Acute Kidney Injury (AKI)

Quick Facts

Study Start:2025-09-05
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05906758

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Hospitalized patients who have AKI at admission or who develop AKI during admission and require invasive coronary angiography will be included in the trial.
  1. * Stabilized renal function manifested by unchanged or downtrending serum creatinine during a 24-hour period prior to enrollment.
  2. * Contraindication for invasive coronary angiography other than AKI.
  3. * Percutaneous coronary intervention is indicated and cannot be postponed by 7 days.
  4. * Need for renal replacement therapy before coronary angiography or planned renal replacement therapy after coronary angiography (if premeditated before coronary angiography).
  5. * Administration of intravascular contrast media during 7 days prior to the coronary angiography or within 6 days after coronary angiography.
  6. * Pregnant patients, prisoners, cognitively impaired subjects, age below 18 years, unable or unwilling to provide informed consent.

Contacts and Locations

Study Contact

Zach Rozenbaum, MD
CONTACT
504-988-5493
zrozenbaum@tulane.edu

Principal Investigator

Zach Rozenbaum, MD
PRINCIPAL_INVESTIGATOR
Tulane University

Study Locations (Sites)

Tulane University Medical Center
New Orleans, Louisiana, 70112
United States
University Medical Center
New Orleans, Louisiana, 70112
United States

Collaborators and Investigators

Sponsor: Tulane University

  • Zach Rozenbaum, MD, PRINCIPAL_INVESTIGATOR, Tulane University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-05
Study Completion Date2026-12

Study Record Updates

Study Start Date2025-09-05
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • Coronary angiography
  • Ultra low contrast

Additional Relevant MeSH Terms

  • Acute Kidney Injury